Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06350734 · ClinicalTrials.gov registry record
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
A clinical trial of Stage 0a Bladder Cancer AJCC v8 and Stage I Bladder Cancer AJCC v8, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 704
- Enrollment target
- 3
- Study locations
NCT06350734 is a study of Stage 0a Bladder Cancer AJCC v8 and Stage I Bladder Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 704 participants, above the 145-participant average among 7 other Stage 0a Bladder Cancer AJCC v8 trials with a reported enrollment target (386% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06350734, a study of Stage 0a Bladder Cancer AJCC v8 and Stage I Bladder Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 704 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study evaluates the effect of bladder cancer treatment on quality of life.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 704 participants |
| Start Date | 2018-10-12 |
| Est. Completion | 2029-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06350734
The ClinicalTrials.gov registry entry for NCT06350734 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 704 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 145-participant average among 7 other Stage 0a Bladder Cancer AJCC v8 trials with a reported enrollment target (386% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage 0a Bladder Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06350734 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06350734 about?
NCT06350734 is a clinical study titled "Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study". This study evaluates the effect of bladder cancer treatment on quality of life.
What is the current status of trial NCT06350734?
This trial is currently recruiting. The enrollment target is 704 participants. The study started on 2018-10-12. Estimated completion is 2029-01-31.
What conditions does trial NCT06350734 study?
This clinical trial studies the following conditions: Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8.
What interventions are being tested in trial NCT06350734?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06350734?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06350734 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage 0a Bladder Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
RECRUITING · Phase 1
-
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RECRUITING · Phase 3
-
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
RECRUITING · NA
-
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.